Inhibition of hepatitis C virus infection by anti‐claudin‐1 antibodies is mediated by neutralization of E2–CD81–Claudin‐1 associations

Sophie E. Krieger, Mirjam B. Zeisel, Christopher Davis, Christine Thumann, Helen J. Harris, Eva K. Schnober, Christopher Mee, Eric Soulier, Cathy Royer, Mélanie Lambotin, Fritz Grunert, Viet Loan Dao Thi, Marlène Dreux, François‐Loïc Cosset, Jane A. McKeating, Catherine Schuster, Thomas F. Baumert – 26 March 2010 – The tight junction protein claudin‐1 (CLDN1) has been shown to be essential for hepatitis C virus (HCV) entry—the first step of viral infection. Due to the lack of neutralizing anti‐CLDN1 antibodies, the role of CLDN1 in the viral entry process is poorly understood.

A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

Giuseppe Cabibbo, Marco Enea, Massimo Attanasio, Jordi Bruix, Antonio Craxì, Calogero Cammà – 26 March 2010 – Knowing the spontaneous outcome of hepatocellular carcinoma (HCC) is important for designing randomized controlled trials (RCTs) of new therapeutic approaches; however, survival of patients in the absence of treatment is highly variable, and prognostic factors influencing outcomes are incompletely defined.

Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon‐based therapy in genotype 1 chronic hepatitis C

Salvatore Petta, Calogero Cammà, Concetta Scazzone, Claudio Tripodo, Vito Di Marco, Antonino Bono, Daniela Cabibi, Giusalba Licata, Rossana Porcasi, Giulio Marchesini, Antonio Craxí – 26 March 2010 – 25‐Hydroxyvitamin D (25[OH]D) can potentially interfere with inflammatory response and fibrogenesis. Its role in disease progression in chronic hepatitis C (CHC) and its relation with histological and sustained virological response (SVR) to therapy are unknown.

Mitogen‐inducible gene‐6 is a negative regulator of epidermal growth factor receptor signaling in hepatocytes and human hepatocellular carcinoma

Markus Reschke, Ingvar Ferby, Ewa Stepniak, Nina Seitzer, David Horst, Erwin F. Wagner, Axel Ullrich – 26 March 2010 – The mitogen‐inducible gene‐6 (mig‐6) is a multi‐adaptor protein implicated in the regulation of the HER family of receptor tyrosine kinases. We have reported recently that mig‐6 is a negative regulator of epidermal growth factor receptor (EGFR)‐dependent skin morphogenesis and tumor formation in vivo. In the liver, ablation of mig‐6 leads to an increase in EGFR protein levels, suggesting that mig‐6 is a negative regulator of EGFR function.

Subscribe to